Biotech stocks remain buoyant, and although funding dipped compared with the preceding two quarters, 1Q09 remained above the dire levels seen last winter. Excluding US partnership monies, the industry pulled in $5.5 billion last quarter, down 31% from 4Q09. Six initial public offerings (IPOs) were completed, bringing funding for public floats up 45% to $391.7 million.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Above water in Q1. Nat Biotechnol 28, 392 (2010). https://doi.org/10.1038/nbt0510-392
Issue Date:
DOI: https://doi.org/10.1038/nbt0510-392
